Dapagliflozin in STEMI

Inclusion Criteria: Patients referred for PPCI meeting the following criteria are eligible for the study: * Ischemic chest discomfort of ≥30 minutes duration, and * Onset of chest pain ≤12 hours prior to entry into the study, and * One of the following High-Risk criteria on a standard 12 lead ECG: a. Anterior STEMI with ST-segment elevation ≥2mm (0.2 mV) in each of at least 2 contiguous precordial leads (V1-V6) b. Extensive non-anterior STEMI defined as ST-segment elevation of \>1mm in two or more contiguous non-anterior leads accompanied by i. 8 or more leads with \> 1 mm ST elevation or depression, or both; OR ii. Sum of ST- segment elevation \>20mm Exclusion Criteria: * Age \< 18 years * Any contraindication to undergo CMR imaging * Killip 4 (Cardiogenic shock on presentation) * Therapy with SGLT2i within last 8 weeks * Type 1 diabetes mellitus * Pregnancy * Nursing mother * Unwilling to use appropriate forms of contraception, as applicable * Chronic symptomatic HF with prior hospitalization for HF within the last year * hospitalization * Known history of prior MI * Any non-CV condition with a life expectancy of less than one year * Previous randomization in the present study * Participation in a study with another investigational device or drug \< four weeks * Inability to provide informed consent * Confirmed ketoacidosis at time of admission * Known severe hepatic impairment (Cirrhosis) * Severe renal impairment (eGFR \< 30 mL/min1.73m2 (based on prior or baseline blood work) * Known severe valvular heart disease * Need for CABG within 90 days based on the results of the initial coronary angiogram * False positive STEMI (based on the results of the coronary angiogram)